Stocks and InvestingStocks and Investing
Thu, July 1, 2021
Wed, June 30, 2021
Tue, June 29, 2021
Mon, June 28, 2021
Fri, June 25, 2021
Thu, June 24, 2021
Wed, June 23, 2021

Robyn Karnauskas Maintained (BTAI) at Strong Buy with Decreased Target to $125 on, Jun 23rd, 2021


Published on 2024-10-27 17:02:40 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $128 to $125 on, Jun 23rd, 2021.

Robyn has made no other calls on BTAI in the last 4 months.



There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 0 agree with Robyn's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Robyn


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $176 on, Tuesday, June 1st, 2021
  • Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021